Skip to main content
Clinical Trials/NCT01957436
NCT01957436
Active, not recruiting
Phase 3

A Prospective Randomised Phase III Study Of Androgen Deprivation Therapy With Or Without Docetaxel With Or Without Local Radiotherapy With Or Without Abiraterone Acetate And Prednisone In Patients With Metastatic Hormone-Naïve Prostate Cancer

UNICANCER77 sites in 2 countries1,173 target enrollmentNovember 13, 2013

Overview

Phase
Phase 3
Intervention
Androgen Deprivation Therapy
Conditions
Metastatic Prostate Cancer
Sponsor
UNICANCER
Enrollment
1173
Locations
77
Primary Endpoint
Survival
Status
Active, not recruiting
Last Updated
last year

Overview

Brief Summary

This is a multi-center phase III study to compare the clinical benefit of androgen deprivation therapy with or without docetaxel with or without local radiotherapy with or without abiraterone acetate and prednisone in patient with metastatic hormone-naïve prostate cancer.

Detailed Description

Eligible patients can be randomize in the trial after his consent form has been signed, and after all inclusion and non-inclusion criteria have been checked. The randomisation will result in the allocation of arm A (ADT +docetaxel), arm B (ADT +docetaxel +Abiraterone), arm C (ADT +docetaxel +radiotherapy) or arm D (ADT +docetaxel +Abiraterone +radiotherapy) in a 1:1:1:1 ratio. The randomization will be stratified (by minimization) according to: * enrolment center, * performance status (0 vs. 1-2) * disease extent: lymph nodes only vs. bone (with or without lymph nodes) vs. presence of visceral metastases. CRPC is defined by cancer progression (either a confirmed PSA rise or a radiological progression) with serum testosterone being at castrated levels (\<0.50 ng/mL). When the CRPC stage is reached, castration (either LHRH agonist or LHRH antagonist) will be maintained in all patients. Investigators will be free to manage patients reaching CRPC at their discretion (using for example docetaxel, zoledronic acid, denosumab, sipuleucel-T, radium-223, cabazitaxel, etc) according to local uses and guidelines. Abiraterone may be used in arm A and C if abiraterone has become the standard treatment for CRPC when this stage is reached.

Registry
clinicaltrials.gov
Start Date
November 13, 2013
End Date
December 2032
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
Male

Investigators

Sponsor
UNICANCER
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Patients with previous definitive local treatment directed to the prostate primary cancer (radiotherapy, brachytherapy, radical prostatectomy, ultrasound, cryotherapy, or other). A previous trans-urethral resection of the prostate (TURP) and previous local treatments of metastases are allowed,
  • Prior cytotoxic chemotherapy or biological therapy for the treatment of prostate cancer,
  • Any chronic medical condition requiring a higher dose of corticosteroid than 5 mg prednisone/prednisolone twice daily,
  • Active infection or other medical condition for which prednisone/prednisolone (corticosteroid) use would be contra-indicated,
  • Previously treated with ketoconazole for prostate cancer for more than 7 days,
  • Prior systemic treatment with an azole drug (e.g. fluconazole, itraconazole) within 4 weeks of randomization,
  • Hypertension not controlled by an anti-hypertensive treatment (systolic BP ≥ 160 mmHg or diastolic BP ≥ 95 mmHg; 3 consecutive measures taken 5 minutes apart),
  • Severe or moderate hepatic impairment (Child - Pugh class C or B)
  • Active or symptomatic viral hepatitis or chronic liver disease (except Gilbert's disease),
  • History of pituitary or adrenal dysfunction,

Arms & Interventions

Arm A

androgen deprivation therapy + docetaxel

Intervention: Androgen Deprivation Therapy

Arm A

androgen deprivation therapy + docetaxel

Intervention: Docetaxel

Arm B

androgen deprivation therapy + docetaxel + abiraterone acetate + prednisone

Intervention: abiraterone acetate

Arm B

androgen deprivation therapy + docetaxel + abiraterone acetate + prednisone

Intervention: Androgen Deprivation Therapy

Arm B

androgen deprivation therapy + docetaxel + abiraterone acetate + prednisone

Intervention: Docetaxel

Arm C

Arm A + radiotherapy

Intervention: radiotherapy

Arm C

Arm A + radiotherapy

Intervention: Androgen Deprivation Therapy

Arm C

Arm A + radiotherapy

Intervention: Docetaxel

Arm D

Arm B + radiotherapy

Intervention: abiraterone acetate

Arm D

Arm B + radiotherapy

Intervention: radiotherapy

Arm D

Arm B + radiotherapy

Intervention: Androgen Deprivation Therapy

Arm D

Arm B + radiotherapy

Intervention: Docetaxel

Outcomes

Primary Outcomes

Survival

Time Frame: 9.5 years after the first inclusion

Overall and radiographic progression-free survival in hormone-naïve prostate cancer patients with low metastatic burden whatever the standard of care received

Secondary Outcomes

  • PSA response rate(9.5 years after the first inclusion)
  • Time to chemotherapy for CRPC(9.5 years after the first inclusion)
  • Castration resistance-free survival (CRFS)(9.5 years after the first inclusion)
  • Serious Genitourinary event-free survival (S-GU-EFS)(9.5 years after the first inclusion)
  • Prostate cancer specific survival(9.5 years after the first inclusion)
  • Quality of life questionnaire - Core 30 (QLQ-C30)(At baseline, 6 months, 18 months, and at the end of treatment (up to 9.5 years))
  • Toxicity (with a specific focus on the use of long-term low-dose steroids)(Throughout study completion, up to 9.5 years)
  • Time to next skeletal-related event(9.5 years after the first inclusion)
  • Time to pain progression(9.5 years after the first inclusion)
  • Correlation of biomarkers with outcome(9.5 years after the first inclusion)
  • Prospective correlative study of PSA response/progression at 8 months after initation of ADT(9.5 years after the first inclusion)
  • Changes in bone mineral density(At baseline, 6 months, 12 months, and 24 months)
  • Functional Assessment of Cancer Therapy - Prostate (FACT-P)(At baseline, 6 months, 12 months, 18 months, and at the end of treatment (up to 9.5 years))

Study Sites (77)

Loading locations...

Similar Trials

Related News

Darolutamide Gains FDA Approval for Metastatic Hormone-Sensitive Prostate Cancer Following ARANOTE Trial Success- Darolutamide (Nubeqa) received FDA approval on June 3, 2025, for treating metastatic hormone-sensitive prostate cancer based on the ARANOTE trial results. - The ARANOTE trial demonstrated efficacy of darolutamide plus androgen deprivation therapy as a doublet regimen, expanding treatment options beyond existing triplet therapies. - NCCN guidelines now include four Category 1 preferred oral agents for mHSPC: abiraterone, apalutamide, enzalutamide, with darolutamide expected to be upgraded from Category 2B status. - The approval provides patients with low-volume metachronous disease an additional oral treatment option that minimizes adverse events while maintaining aggressive therapeutic approach.mCSPC Prognosis Linked to AR, Neuroendocrine Markers, and Tumor Suppressor Gene Alterations- Analysis of the PEACE-1 trial reveals that AR and neuroendocrine marker expression can identify patient subgroups in metastatic castration-sensitive prostate cancer (mCSPC) with varying outcomes. - Patients with AR-high luminal tumors showed better prognoses, while those with neuroendocrine prostate cancer exhibited worse outcomes, particularly driven by neuroendocrine marker expression. - Alterations in TP53, PTEN, and RB1 tumor suppressor genes were prognostically significant, with patients having fewer than two alterations showing improved overall survival. - Neither AR nor neuroendocrine biomarkers predicted response to abiraterone acetate plus prednisone, leaving the need for predictive biomarkers for abiraterone benefit in mCSPC undetermined.Triplet Therapy vs. Doublet Therapy in Metastatic Prostate Cancer: A Treatment Debate- Triplet therapy, combining ADT, ARPIs, and docetaxel, is considered the most effective first-line treatment for metastatic hormone-sensitive prostate cancer (mHSPC) due to its multi-targeted approach. - The PEACE-1 and ARASENS trials demonstrated that triplet therapy significantly improves overall survival (OS) and progression-free survival (PFS) compared to doublet therapy in mHSPC patients. - Doublet therapy, such as ADT plus ARPIs, still holds a role in mHSPC treatment, especially considering the heterogeneity of prostate cancer and varying patient risk profiles. - Ongoing debate centers on tailoring treatment approaches based on disease volume and risk, with a need for trials evaluating chemotherapy plus APRI and ADT versus placebo plus APRI and ADT.